YES...that was real exploratory...and they obviously felt the need to error on the safer side...JL was arguing for a possibly greater dosing and longer...I would suggest that this time ...He might have reminded them of the last encounter...and of his own trial experiences with Leronlimab...in my view... he is the greater authority on Leronlimab and its MOA.